Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity.

Autor: Stuckey JI; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Cantone NR; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Côté A; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Arora S; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Vivat V; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Ramakrishnan A; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Mertz JA; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Khanna A; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Brenneman J; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Gehling VS; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Moine L; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Sims RJ 3rd; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Audia JE; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Trojer P; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Levell JR; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA., Cummings RT; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA. Electronic address: richard.cummings@constellationpharma.com.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2021 Jan-Jun; Vol. 296, pp. 100349. Date of Electronic Publication: 2021 Jan 30.